Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

瑋俊生物科技有限公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

SUPPLEMENTAL ANNOUNCEMENT AND FURTHER DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcements of Wai Chun Bio-Technology Limited (the "**Company**") dated 12 December 2025 (the "**1st Announcement**"), 6 January 2026, 27 January 2026 and 25 February 2026 (the "**Announcements**") in relation to (1) the Loan Agreement entered into between the Company and the Borrower; and (2) the Non-compliance. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

As previously disclosed in the 1st Announcement, the Company has received written Shareholder's approval from Chinese Success Limited, holding 91,550,243 Shares (representing approximately 51.30% of the issued share capital of the Company as at the date of this announcement) to approve the Drawdowns. Accordingly, it was stated in the announcement that no general meeting of the Company will be convened for the purpose of approving the Drawdowns pursuant to Rule 14.44 of the Listing Rules.

Pursuant to Rule 14.41 of the Listing Rules, the circular must be despatched to the shareholders of the listed issuer if the transaction is approved or is to be approved by way of written shareholders' approval from a shareholder under Rule 14.44 of the Listing Rules, within 15 business days after publication of the Announcement (the "**Circular for Written Approval**"). Based on this requirement, the Circular for Written Approval should be despatched by 7 January 2026, which marks 15 business days from the publication date of the 1st Announcement.

As the time for the Company to despatch the Circular is longer than originally contemplated, the despatch date of the Circular was postponed beyond 7 January 2026. Accordingly, the Company hereby wishes to inform the Shareholders that the Board has now decided to hold a general meeting to approve the Drawdowns, instead of relying on the written Shareholder's approval pursuant o Rule 14.44 of the Listing Rules obtained from Chinese Success Limited. As such, a notice of extraordinary general meeting shall be contained in the Circular to be despatched to the Shareholders for the Shareholders' attention.

FURTHER DELAY IN DESPATCH OF CIRCULAR

As disclosed in the Announcements, the Circular containing, among others, further details of the Drawdowns, is expected to be despatched to the Shareholders no later than 28 March 2026. As additional time is required for the Company to prepare and finalise certain information in the Circular, the despatch date of the Circular has been postponed to on or before 25 April 2026.

By Order of the Board
Wai Chun Bio-Technology Limited
Lam Ka Chun
Chairman

Hong Kong, 27 March 2026

As at the date of this announcement, the Board comprises:

Executive Director:
Mr. Lam Ka Chun *(Chairman and Chief Executive Officer)*

Independent Non-executive Directors:
Mr. Wong Po Keung
Mr. Wang Ziniu
Ms. Xu Huiling